Among the 351 patients who received five continuous years of lecanemab in the Clarity AD long-term extension, 62% of those with low tau levels at baseline actually showed measurable improvement on the CDR-SB clinical scale, not merely stability. That figure, presented at the CTAD conference in Boston on November 16, cuts against the standard framing of Alzheimer’s therapy as a holding action. For the broader trial population, five years of treatment reduced the relative risk of progressing to the next disease stage by 36% compared with the ADNI natural-history cohort, and the gap between treated patients and the ADNI comparator widened each year: 1.00 CDR-SB points at three years, 1.78 at four, and 2.05 at five.

The low-tau finding is the number worth watching most closely. Tau accumulation tracks closely with cognitive decline, so patients with low tau at enrollment represent an earlier biological window of disease. In that subgroup, 69% showed no decline (stable or improvement) on the ADCS MCI-ADL activities scale at five years, and 62% showed improvement on the CDR-SB scale. The pattern holds across cognition as well:. Eisai and Biogen have held FDA approval for lecanemab since July 2023, and Lilly’s donanemab entered the same early-AD space with FDA approval in July 2024, making durability data a genuine commercial differentiator, not just an academic exercise.

Safety held consistent with what the 18-month core study showed. ARIA-E, the edema-type imaging abnormality that defined early risk concerns for this drug class, occurred in 13.5% of patients during the first 12 months and fell sharply after that: 3.6% in year two, then 3.6% in year two, then 1.1%, 1.3%, and 0.6% in each subsequent interval. No new safety signals emerged across five years. That declining incidence curve is clinically meaningful because it suggests the risk front-loads early in treatment rather than accumulating indefinitely, which matters for how physicians counsel patients about long-term commitment to the therapy.

The Clarity AD LTE enrolled 95% of core-study completers, an unusually high retention rate that reduces the concern that only the healthiest patients contributed to the five-year data. What the program has not yet answered is how patients with higher tau burden at baseline fare over the same horizon, since the low-tau improvement signal depends entirely on starting treatment before tau pathology is advanced. That question will determine how broadly these long-term benefit numbers can be applied in clinical practice.

Source link: https://www.prnewswire.com/news-releases/new-five-year-lecanemab-data-from-clarity-ad-study-long-term-extension-presented-at-ctad-2026-302941089.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.